English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Oral anticoagulants, including direct oral anticoagulants ( DOAC s), are usually required in atrial fibrillation ( AF ) patients who are at a high risk of thromboembolism ( TE ), even if they had undergone catheter ablation ( CA ). Although several studies have reported the safety and efficacy of  DOAC s around  CA  in  AF  patients, there are only limited data regarding the midterm incidence of  TE  and bleeding complications post‐ CA  among  AF  patients treated with warfarin or  DOAC s.    Methods  We studied 629  AF  patients (mean age: 65.3 ± 10.3 years; 442 men) undergoing  CA , to calculate the midterm incidence of  TE  and bleeding complications associated with warfarin or  DOAC s.    Results  In total, 292 patients used warfarin and 337 used  DOAC s (dabigatran: 90 patients; rivaroxaban: 137; and apixaban: 110). At baseline, the  CHA 2 DS 2‐ VAS c and  HAS ‐ BLED  scores were similar between the 2 groups. During a median follow‐up period of 7 months, no  TE  complications occurred. The warfarin group had a significantly higher bleeding event rate than did the  DOAC s group (all bleeding complications: 32 [11.0%] vs 15 [4.5%], respectively,  P  = .002). The rate of all bleeding complications was significantly higher in the warfarin group than in the  DOAC s group (10.1% vs 3.7%, respectively, at 10 months;  P  = .024). In Cox proportional hazards modeling,  DOAC  use was significantly associated with a decreased risk of bleeding (adjusted hazard ratio: 0.497; 95% confidence interval: 0.261‐0.906,  P  = .022).    Conclusions  Direct oral anticoagulant use in  AF  patients undergoing  CA  may be associated with a similar risk of  TE  as warfarin but is associated with a lower risk of bleeding.

journal of arrhythmia

Comparison of direct oral anticoagulants and warfarin regarding midterm adverse events in patients with atrial fibrillation undergoing catheter ablation